Related Experiment Video
Updated: Apr 26, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.7K
Functional characterization of platelets in patients with arterial erectile dysfunction
S La Vignera1, R A Condorelli, G Burgio
1Section of Endocrinology, Andrology and Internal Medicine, Department of Internal Medicine and Systemic Disease, University of Catania, Catania, Italy.
Andrology
|July 30, 2014
Summary
Mean platelet volume (MPV) and platelet vitronectin receptor (αVβ3) expression are significantly elevated in men with arterial erectile dysfunction (ED) lacking traditional cardiovascular risk factors, suggesting potential roles as novel risk markers.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Urology
Background:
- Arterial erectile dysfunction (ED) is linked to cardiovascular and metabolic risks.
- Some arterial ED cases lack identifiable cardiovascular risk factors.
- Platelet function markers like mean platelet volume (MPV) and vitronectin receptor (αVβ3) expression are implicated in cardiovascular risk and platelet adhesion.
Purpose of the Study:
- To investigate MPV and αVβ3 expression in patients with arterial ED without traditional cardiovascular risk factors.
- To compare these platelet markers between patients with arterial ED and healthy controls.
Main Methods:
- The study included 15 patients diagnosed with arterial ED and no cardiovascular risk factors.
- MPV and the percentage of platelets expressing αVβ3 were measured.
- Values were compared to a control group with normal penile hemodynamics.
Main Results:
- Patients with arterial ED exhibited significantly higher mean MPV (11.25 fL vs. 9.88 fL) and αVβ3 expression (7.39% vs. 2.07%) compared to controls (p < 0.001 for both).
- A negative correlation was found between peak systolic velocity and MPV or αVβ3.
- MPV and αVβ3 showed a positive correlation with each other.
Conclusions:
- This study demonstrates elevated MPV and αVβ3 expression in arterial ED patients without cardiovascular risk factors.
- These platelet parameters may serve as potential indicators of underlying cardiovascular risk in this patient group.
Related Concept Videos
01:22Formation of the Platelet Plug
6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
01:18Structure and Function of Platelets
6.9K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
6.9K
01:30Peripheral Artery Disease I: Introduction
655
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
655
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
815
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
815
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
758
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
758